EGFR and colorectal cancer: The use of anti-EGFR monoclonal antibodies (mAb anti-EGFRs) in colorectal cancer has shown that KRAS and NRAS represent the main resistance mechanisms to this type of treatment and are thus used in clinical practice to select the patients who should not be treated with anti-EGFR therapy11.